TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance
February 20, 2020 7:11 AM ESTTherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $12.83 million.
4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Companys Financial Guidance Full-Year... More